Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease

Scolaris Content Display Scolaris Content Display

Ir a:

Analysis 1.1

Comparison 1 Infliximab versus placebo, Outcome 1 Remission rate.

Analysis 1.2

Comparison 1 Infliximab versus placebo, Outcome 2 Clinical Response.

Analysis 2.1

Comparison 2 CDP571 versus placebo, Outcome 1 Remission rate.

Analysis 2.2

Comparison 2 CDP571 versus placebo, Outcome 2 Clinical Response.

Analysis 3.1

Comparison 3 Etanercept versus placebo, Outcome 1 Remission rate.

Analysis 3.2

Comparison 3 Etanercept versus placebo, Outcome 2 Clinical response.

Comparison 1. Infliximab versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Remission rate Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

2 Clinical Response Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

Comparison 1. Infliximab versus placebo

Comparison 2. CDP571 versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Remission rate Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

2 Clinical Response Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

Comparison 2. CDP571 versus placebo

Comparison 3. Etanercept versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Remission rate Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

2 Clinical response Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

Comparison 3. Etanercept versus placebo